Kamada Ltd (KMDA) has disclosed a new risk, in the Innovation / R&D category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kamada Ltd’s reliance on externally managed Investigator-Initiated Clinical Trials exposes it to risks stemming from limited control over study design, conduct, and data integrity. If investigators fail to meet regulatory or quality standards, Kamada Ltd may face unreliable or unfavorable data that undermines its ability to support regulatory filings and product commercialization.
Because intellectual property arising from these trials typically remains with the external investigators or institutions, Kamada Ltd may be unable to secure rights to valuable discoveries or data generated with its products. This structural limitation could prevent the company from fully leveraging clinical insights gained through IITs, constraining its competitive positioning and long-term growth prospects.
The average KMDA stock price target is $14.00, implying 63.74% upside potential.
To learn more about Kamada Ltd’s risk factors, click here.